Diamond Equity Predicts MAIA Biotechnology FY2025 Earnings

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Stock analysts at Diamond Equity dropped their FY2025 earnings per share (EPS) estimates for MAIA Biotechnology in a research report issued to clients and investors on Monday, November 10th. Diamond Equity analyst H. Diamond now forecasts that the company will earn ($0.74) per share for the year, down from their prior forecast of ($0.72). The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($1.30) per share.

MAIA Biotechnology Stock Down 4.5%

NYSEAMERICAN:MAIA opened at $1.07 on Thursday. MAIA Biotechnology has a twelve month low of $1.05 and a twelve month high of $2.74. The stock has a market cap of $39.62 million, a P/E ratio of -1.47 and a beta of -0.01. The firm’s fifty day simple moving average is $1.47 and its 200 day simple moving average is $1.65.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Centerpoint Advisory Group purchased a new position in MAIA Biotechnology during the second quarter valued at $28,000. Marshall Wace LLP purchased a new stake in shares of MAIA Biotechnology during the second quarter valued at approximately $29,000. Jane Street Group LLC bought a new stake in shares of MAIA Biotechnology in the 2nd quarter worth $52,000. Geode Capital Management LLC increased its holdings in MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after buying an additional 7,746 shares in the last quarter. Finally, Centric Wealth Management raised its holdings in shares of MAIA Biotechnology by 740.2% during the second quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock valued at $1,032,000 after purchasing an additional 505,150 shares during the last quarter. Hedge funds and other institutional investors own 5.65% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.